IGF1R and non-small cell lung carcinoma: A fully humanized anti-IGF1R monoclonal antibody (figitumumab) has been tested in phase III clinical trials; however, no statistically significant improvement was demonstrated by administering figitumumab along with standard chemotherapy to patients with advanced non-small cell lung cancer (NSCLC) [15].